title: Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
abstract: We report the case of a HER2(+) breast cancer patient, with early relapse, refractory to HER2-targeted therapy and treated with eribulin mesylate. The patient progressed during two different HER2 target therapies: trastuzumab as adjuvant/first-line treatment and lapatinib as second-line treatment. The patient underwent nine cycles of eribulin (1.23 mg/m(2) days 1-8 every 3 weeks). The therapy was well tolerated. Restaging with computed tomography after the second cycle of treatment demonstrated stable disease. After nine cycles of eribulin therapy the patient experienced disease progression and she died 6 months later. This case report provides further insights regarding the use of eribulin mesylate as third-line treatment in a HER2(+) breast cancer patient.
authors.affiliation: Medical Oncology Unity, Santa Maria delle Croci Hospital, Ravenna, Italy.
authors.forename: Claudia
authors.initials: C
authors.lastname: Casanova
authors.affiliation: Medical Oncology Unity, Santa Maria delle Croci Hospital, Ravenna, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Verlicchi
authors.affiliation: Medical Oncology Unity, Santa Maria delle Croci Hospital, Ravenna, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Mazza
authors.affiliation: Medical Oncology Unity, Santa Maria delle Croci Hospital, Ravenna, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Dazzi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000627:therapeutic use*; D000077341:Lapatinib; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D019233:Retreatment; D000068878:Trastuzumab / Q000008:administration & dosage; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C490954:eribulin; D000095662:Polyether Polyketides
keywords: HER2+ breast cancer patient; eribulin mesylate; trastuzumab